OverviewSuggest Edit

Cambrex is a global market leader in branded and generic small molecule active pharmaceutical ingredients (APIs), advanced intermediates, custom development and manufacturing and controlled substances. Our pharmaceutical products, technologies and expertise accelerate your small molecule therapeutics into the market.

TypePublic
Founded1981
HQEast Rutherford, NJ, US
Websitecambrex.com
Employee Ratings3.6
Overall CultureC-

Latest Updates

Employees (est.) (Dec 2018)1,732(+42%)
Job Openings87
Revenue (FY, 2018)$532.1 M
Share Price (Dec 2019)$60
Cybersecurity ratingAMore

Key People/Management at Cambrex

Thomas Loewald

Thomas Loewald

Chief Executive Officer
Tom Vadaketh

Tom Vadaketh

Executive Vice President and Chief Financial Officer
Samantha M. Hanley

Samantha M. Hanley

Senior Vice President and General Counsel
Robert Green

Robert Green

Executive Vice President and Chief Financial Officer
Dorothy Donnelly-Brienza

Dorothy Donnelly-Brienza

Senior Vice President and Chief Human Resources Officer
Show more

Cambrex Office Locations

Cambrex has offices in East Rutherford, Charles City and Björkborn
East Rutherford, NJ, US (HQ)
1 Meadowlands Plaza
Charles City, IA, US
1205 11th St
Show all (3)

Cambrex Financials and Metrics

Cambrex Revenue

Embed Graph
View revenue for all periods
Cambrex's revenue was reported to be $532.09 m in FY, 2018
USD

Revenue (Q3, 2019)

148.6m

Gross profit (Q3, 2019)

50.9m

Gross profit margin (Q3, 2019), %

34.3%

Net income (Q3, 2019)

9.5m

EBIT (Q3, 2019)

17.5m

Market capitalization (5-Dec-2019)

2.0b

Closing stock price (5-Dec-2019)

60.0

Cash (30-Sept-2019)

80.8m

EV

2.4b
Cambrex's current market capitalization is $2 b.
USDQ2, 2011

Financial Leverage

2.9 x
Show all financial metrics

Cambrex Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Cambrex Online and Social Media Presence

Embed Graph

Cambrex Company Culture

  • Overall Culture

    C-

    64/100

  • CEO Rating

    B+

    73/100

  • Compensation

    D

    56/100

Learn more on Comparably

Cambrex News and Updates

Cambrex Introduces New Kilogram-Scale GMP Manufacturing Capabilities at Tallinn, Estonia Facility

EAST RUTHERFORD, N.J., May 26, 2021 /PRNewswire/ -- Cambrex today announced the completion of an investment project at its facility in Tallinn, Estonia to upgrade its kilogram-scale laboratory to undertake the manufacture of pharmaceutical intermediates under current good manufacturing...

Cambrex Expands Analytical Services Capabilities at Longmont, Colorado, Facility

EAST RUTHERFORD, N.J., May 5, 2021 /PRNewswire/ -- Cambrex today announced an expansion of cGMP analytical testing capabilities at its site in Longmont, Colorado. Existing space at the site has been repurposed with cutting edge technologies and doubles the footprint of the laboratory...

Cambrex Completes Major Expansion of Solid Form Screening Facility in Edinburgh

EAST RUTHERFORD, N.J., Oct. 12, 2020 /PRNewswire/ -- Cambrex, announced today the completion of an expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland. This major expansion project has seen the facility's total footprint doubled to...

Cambrex Increases Flexible Manufacturing Capacity at Karlskoga, Sweden Facility

East Rutherford, NJ – July 1, 2020 – Cambrex, the leading small molecule company providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it is investing $3.6 million at its Karlskoga, Sweden facility to increase flexible drug substance m…

Cambrex Completes Biopharmaceutical Expansion at its Durham, NC Facility

EAST RUTHERFORD, N.J., April 07, 2020 (GLOBE NEWSWIRE) -- Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced it has completed an expansion of its biopharmaceutical analysis capabilities at the…

Cambrex Wins Third API Development Award at CPhI Worldwide

EAST RUTHERFORD, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, has won the ‘Excellence in Pharma: API Development’ category at the annual C…
Show more

Cambrex Blogs

Cambrex Invests c.$3 Million to Upgrade Generic API Manufacturing Facilities at Milan, Italy Site

East Rutherford, NJ – October 8, 2018 – Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that it is investing approximately $3 million to increase the capacity and ef…

Cambrex to present at upcoming investor conferences in September

East Rutherford, NJ – August 29, 2018 – Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that company management will present at the following investor conferences in September: 2018 Wells Fargo …

Cambrex to Announce Second Quarter 2018 Financial Results on August 2, 2018

East Rutherford, N.J., July 27, 2018 (GLOBE NEWSWIRE) – Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that second quarter 2018 financial results will be released on Thursday, August 2, 2018 bef…

Cambrex to Acquire Halo Pharma, Adding Drug Development and Finished Dosage Capabilities to Global API Manufacturing Network

— Conference Call at 8:30 a.m. ET Today — East Rutherford, NJ – July 23, 2018 – Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced it has entered into a definitive agreement to acquire Halo Pharma …

Cambrex Expands Generic API Research and Development Capabilities at Milan, Italy Site

East Rutherford, NJ – June 12, 2018 – Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it will expand research and development capabilities at its site in Paullo, Milan, Italy. The investm…

Cambrex To Present At The Jefferies 2018 Global Healthcare Conference

East Rutherford, NJ – June 1, 2018 – Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcar…
Show more

Cambrex Frequently Asked Questions

  • When was Cambrex founded?

    Cambrex was founded in 1981.

  • Who are Cambrex key executives?

    Cambrex's key executives are Thomas Loewald, Tom Vadaketh and Samantha M. Hanley.

  • How many employees does Cambrex have?

    Cambrex has 1,732 employees.

  • What is Cambrex revenue?

    Latest Cambrex annual revenue is $532.1 m.

  • What is Cambrex revenue per employee?

    Latest Cambrex revenue per employee is $307.2 k.

  • Who are Cambrex competitors?

    Competitors of Cambrex include Siegfried Holding, Johnson Matthey and Lonza.

  • Where is Cambrex headquarters?

    Cambrex headquarters is located at 1 Meadowlands Plaza, East Rutherford.

  • Where are Cambrex offices?

    Cambrex has offices in East Rutherford, Charles City and Björkborn.

  • How many offices does Cambrex have?

    Cambrex has 3 offices.